Bristol Myers Squibb (CELG-RI) Gains from Sales and Divestitures (2011 - 2012)
Bristol Myers Squibb (CELG-RI) posted quarterly Gains from Sales and Divestitures of -$3.3 million for Q4 2012, up 1.74% YoY from -$3.3 million in Q1 2012, and up 1.74% sequentially from -$3.4 million in Q4 2011.
Bristol Myers Squibb (CELG-RI) Gains from Sales and Divestitures (2011 - 2012) Analysis & Trends
Bristol Myers Squibb has disclosed Gains from Sales and Divestitures across 2 years of filings, most recently posting -$3.3 million for Q4 2012.
- In Q4 2012, Gains from Sales and Divestitures rose 1.74% year-over-year to -$3.3 million; the TTM figure through Dec 2012 stood at -$3.3 million (up 1.74% YoY), while the FY2012 annual figure was -$3.3 million, up 1.74% from the prior year.
- Gains from Sales and Divestitures advanced to -$3.3 million in Q4 2012, from -$3.4 million in the prior quarter.
- Over the last five years, Gains from Sales and Divestitures for CELG-RI reached as high as -$3.3 million in Q4 2012 and fell as low as -$3.4 million in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -3.34 Mn |
| Dec 31, 2012 | -3.34 Mn |
| Dec 31, 2011 | -3.40 Mn |
| Dec 31, 2011 | -3.40 Mn |